Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group

Erica C Nakajima, Amber Simpson, Jan Bogaerts, Elisabeth G E de Vries, Richard Do, Elena Garalda, Greg Goldmacher, Paul E Kinahan, Philippe Lambin, Barbara LeStage, Qin Li, Frank Lin, Saskia Litière, Raquel Perez-Lopez, Nicholas Petrick, Lawrence Schwartz, Lesley Seymour, Lalitha Shankar, Scott A Laurie*

*Corresponding author voor dit werk

    Onderzoeksoutput: ArticleAcademicpeer review

    7 Citaten (Scopus)
    69 Downloads (Pure)

    Samenvatting

    Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials.

    Originele taal-2English
    Artikelnummere2300687
    Aantal pagina's8
    TijdschriftJCO Precision Oncology
    Volume8
    DOI's
    StatusPublished - apr.-2024

    Vingerafdruk

    Duik in de onderzoeksthema's van 'Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group'. Samen vormen ze een unieke vingerafdruk.

    Citeer dit